🎧 ▶️ Press play below to listen.
🇪🇸 Spanish (Latinoamérica)
Este audio explica por qué el ayuno intermitente ofrece mejores resultados cardíacos que las sulfonilureas en personas con diabetes, usando evidencia clara y práctica.
Presiona el botón de reproducir para escuchar.
🇨🇳 中文（简体）
本音频说明为何间歇性禁食在糖尿病患者的心脏事件结果上优于磺脲类药物，并以清晰证据加以解释。
请按下方的播放按钮收听。
I. Introduction: The Ongoing Battle in Diabetes Treatment
Type 2 diabetes is now one of the major chronic diseases of our time. According to the Centers for Disease Control and Prevention (CDC), in the United States, more than 29.7 million people had been diagnosed withdiabetes (about 8.9 % of the population) as of 2021. CDC
Many of these patients rely on medications to lower their blood sugar. One of the older, widely-used classes is the sulfonylureas (SUs). These drugs are often chosen because they are inexpensive and familiar to physicians.
Yet for many patients and doctors, the question is: Are SUs simply forcing blood sugar down, or are they influencing the body’s biology in ways that may hurt in the long run?
In contrast, rising interest attaches to non-drug strategies like intermittent fasting — not to replace medication blindly, but to work with the body’s natural rhythms and repair processes.
In this article, we’ll explore how SUs work, how many people use them, how they force insulin secretion, and why that forced approach may have serious downsides. We’ll then compare that with how lifestyle-based strategies can restore metabolic health rather than accelerate wear and tear.
II. What Are Sulfonylureas (SUs)?
Definition and Background
Sulfonylureas are a class of oral medications used to treat type 2 diabetes mellitus (T2DM). NCBI They trace back to the 1950s and were among the first widely used pills to force insulin release from the pancreas. NCBI
Common second-generation SUs in the U.S. include:
- Glipizide
- Glyburide (also known as glibenclamide)
- Glimepiride
How Many People Use Them?
While the use of SUs in the U.S. has declined over recent decades, they remain common. A U.S. national survey (NHANES) found that among adults with diagnosed diabetes the prevalence of SU use dropped from about 39.9 % in 1999–2002 to about 24.5 % in 2015–2018. PMC
Other sources report around 31 % of U.S. diabetes patients using SUs at a certain point.
Globally, in low- and middle-income countries (LMICs), SUs remain important because of cost concerns, and many guidelines still allow their use in certain settings. PMC
Why They Are Still Used
- Cost: SUs remain inexpensive compared to newer drugs (for example, glipizide or glyburide may cost tens of dollars per year versus hundreds or thousands for newer agents). Medscape
- Familiarity: Clinicians have long experience with SUs; they are well-known, generically available, and widely used.
- Guideline Positioning: Although many major diabetes treatment guidelines now favour newer agents (especially when cardiovascular or kidney disease is present), SUs still appear in many national and international guideline documents as second-line options or in cost-sensitive settings. PMC
III. How Sulfonylureas Work — and Why They’re a Double-Edged Sword
A. The Normal Process: How the Pancreas Releases Insulin
In healthy metabolism, beta cells in the pancreas continuously monitor the level of glucose in the blood.
- After a meal, rising glucose enters these beta cells through GLUT2 transporters.
- Inside, glucose is broken down to produce ATP (energy molecules).
- This ATP closes tiny “gateways” on the cell surface called ATP-sensitive potassium channels.
- Once those channels close, the cell’s electrical balance changes — it depolarizes, opening calcium channels.
- Calcium rushes in, triggering the release of insulin stored in small granules inside the cell.
This natural system is finely tuned: insulin is released only when needed and in amounts appropriate to the body’s energy state.
B. The Sulfonylurea Shortcut
Sulfonylureas bypass this normal glucose-sensing process. They bind to a specific receptor (SUR1, or sulfonylurea receptor 1) on the same Potassium ATP channel. By doing so, they force the channel to stay closed, even when blood glucose is not particularly high.
This triggers the same electrical cascade—membrane depolarization, calcium influx, and insulin release—but without regard to whether the pancreas or the body actually needs it.
In simpler terms, sulfonylureas “squeeze” the pancreas to release insulin, even from cells that may already be worn down or energy-deprived.
That’s why many physicians describe this effect as revving a tired engine—you get a temporary boost, but at the cost of faster wear and tear.
C. What Happens Over Time
At first, this forced insulin release works: blood glucose levels drop, and lab results appear “better.”
But because the pancreas is being continually pushed, several problems begin to appear:
Beta-cell fatigue: The cells that make insulin lose their ability to rest and recover.
Declining response: Over months or years, the same dose of sulfonylurea produces less effect, prompting dose escalation.
Hypoglycemia risk: Because the mechanism is not glucose-dependent, insulin may surge even when blood sugar is low, leading to dizziness, sweating, confusion, or fainting.
Increased insulin levels (hyperinsulinemia): Chronic overproduction of insulin sets off a chain reaction that promotes fat gain, inflammation, and vascular damage — topics explored in the next section.
D. Summary
Sulfonylureas provide short-term control by forcing insulin release rather than restoring normal insulin sensitivity. They may help numbers on paper, but they do not address the underlying insulin resistance driving Type 2 diabetes.
Over time, this approach can accelerate the very disease process it aims to treat — setting the stage for hyperinsulinemia, weight gain, and cardiovascular complications.
IV. The Downside: Hyperinsulinemia and Its Domino Effects
A. What Is Hyperinsulinemia?
Hyperinsulinemia means there’s too much insulin circulating in the blood for too long.
It’s often silent — a person’s fasting glucose may look “normal,” yet their insulin levels remain persistently high.
Sulfonylureas (SUs) make this worse by forcing the pancreas to secrete insulin beyond what’s naturally needed.
At first glance, this seems beneficial because blood sugar drops.But in reality, high insulin is a metabolic alarm bell — signaling that the body’s cells are becoming resistant to insulin’s effects.
The pancreas responds by releasing even more insulin, creating a vicious cycle that worsens metabolic damage.
B. The Biological Chain Reaction of Too Much Insulin
Chronically elevated insulin affects almost every major system in the body:
- Fat Storage and Weight Gain
- Insulin is an anabolic or “storage” hormone. It tells the body to store calories rather than burn them.
- High insulin blocks fat breakdown (lipolysis) and promotes visceral fat accumulation — the deep belly fat strongly linked to diabetes and heart disease.
- Hypertension (High Blood Pressure)
- Insulin causes the kidneys to retain sodium and water, increasing blood volume and blood pressure.
- It also stimulates the sympathetic nervous system, raising heart rate and vascular tone.
- Endothelial Dysfunction
- Insulin resistance damages the endothelium, the delicate inner lining of blood vessels.
- This reduces nitric oxide availability, causing blood vessels to stiffen and lose their ability to dilate — a key step toward atherosclerosis.
- Fatty Liver and Elevated Triglycerides
- Insulin directs excess glucose toward de novo lipogenesis — the conversion of sugar into fat within the liver.
- Over time, this leads to fatty liver disease, high triglycerides, and further insulin resistance.
- Heart and Vascular Stiffening
- Chronic hyperinsulinemia thickens the walls of small arteries, a process called arteriolosclerosis.
- The heart must pump harder against this resistance, predisposing to diastolic dysfunction and eventual heart failure.
- Accelerated Aging and Inflammation
- Excess insulin activates mTOR and other growth pathways that suppress autophagy — the body’s cellular clean-up process.
- The result is accumulation of damaged proteins, oxidative stress, and chronic low-grade inflammation.
C. The Clinical Picture: Why Numbers Can Deceive
A diabetic patient on sulfonylureas may see “improved” glucose readings but still experience:
- Progressive weight gain
- Elevated triglycerides
- Rising blood pressure
- Fatty liver
- Fatigue and swelling
That’s because while the blood sugar appears controlled, the underlying metabolic dysfunction is worsening.
In this way, sulfonylureas can create the illusion of progress while deepening insulin resistance — a case of treating the symptom but feeding the disease.
D. The Domino Effect on the Heart
High insulin doesn’t just make blood vessels stiff; it makes the heart more vulnerable to injury.
When a heart attack strikes, those chronically exposed to high insulin have poorer recovery and larger infarcts.
This sets the stage for the next section — the most serious consequence of all: increased cardiovascular mortality among people taking sulfonylureas.
V. The Hidden Cost: Sulfonylureas and Heart Disease
A. Why Diabetes Drugs Should Protect the Heart — but Some Don’t
A truly effective diabetes therapy should do more than lower glucose — it should also protect the heart. Unfortunately, sulfonylureas (SUs) often fail this crucial test.
People with Type 2 diabetes are two to four times more likely to die from heart disease than those without it. Instead of providing cardiac protection, they can increase the risk of heart failure and death following a heart attack.
B. How High Insulin Damages the Cardiovascular System
As discussed earlier, sulfonylureas force the pancreas to pump out insulin even when the body doesn’t need it.
This chronic hyperinsulinemia affects the heart in multiple ways:
- Vascular constriction: High insulin activates the sympathetic nervous system, raising heart rate and vascular tone.
- Sodium retention: It causes the kidneys to retain salt and water, increasing blood volume and workload on the heart.
- Endothelial injury: Constant insulin exposure stiffens arteries and promotes plaque formation.
- Inhibited ischemic preconditioning: Most damaging of all, sulfonylureas block a natural heart-protective mechanism.
C. Ischemic Preconditioning — The Heart’s Built-In Defense
When blood flow to part of the heart is briefly reduced and then restored — as can happen in daily life — the heart adapts by becoming more resistant to future, more severe ischemia. This is called ischemic preconditioning, and it limits damage if a heart attack occurs.
However, sulfonylureas interfere with this protection. They block the same Potassium ATP channels in heart muscle that they block in pancreatic beta cells.
When these cardiac channels are inhibited, blood flow cannot be properly regulated during oxygen deprivation, and the heart suffers larger infarcts (areas of dead tissue) when an attack happens.
Animal studies first showed this decades ago:
- In 1993, Toombs and colleagues demonstrated that glibenclamide reversed the protective benefits of ischemic preconditioning in rabbits (Cardiovascular Research, 27: 617–622).
Later human data confirmed the pattern — diabetics taking sulfonylureas had larger heart attacks and poorer recovery.
D. Human Evidence: Worse Outcomes After Myocardial Infarction
Several key studies and agencies have warned of the cardiac dangers of SUs:
- National Diabetes Center (2000): Advised against high-dose sulfonylureas because of increased cardiovascular mortality.
- Journal of the American Heart Association (2017):
Roumie et al. reported that patients starting sulfonylureas had higher risks of heart failure and cardiovascular death compared to those starting metformin. - U.S. FDA (2019): Issued a mandatory label warning for all sulfonylureas under Title 21 CFR § 310.517, stating in boldface:
“Special Warning on Increased Risk of Cardiovascular Mortality:
The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin.”
These findings reinforce a consistent message: forcing insulin production improves lab numbers but may increase the odds of dying from heart disease.
E. Mechanistic Summary
| Mechanism | Consequence |
|---|---|
| Pancreatic Potasiium ATP blockade | Forced insulin release → hyperinsulinemia |
| Cardiac Potassium ATP blockade | Loss of ischemic preconditioning → larger infarct |
| Renal sodium retention | Hypertension, fluid overload |
| Endothelial dysfunction | Atherosclerosis, reduced nitric-oxide signaling |
| Sympathetic activation | Tachycardia, increased oxygen demand |
Together these effects create a metabolic-cardiac trap: blood sugar improves on paper, while the heart quietly grows weaker and more vulnerable.
F. The Turning Point
Modern diabetes care increasingly prioritizes drugs that improve cardiovascular outcomes — such as metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors.
Yet sulfonylureas remain in use worldwide, especially where cost limits options. This underscores the need for inexpensive, physiologic strategies like intermittent fasting, which can lower glucose and insulin without harming the heart.
VI. How Intermittent Fasting Offers a Better Path
A. Working With the Body, Not Against It
Where sulfonylureas force the pancreas to release insulin, intermittent fasting allows the body to reset its hormonal and metabolic balance. Fasting doesn’t fight biology — it uses it.
By alternating between periods of eating and not eating, the body naturally transitions from sugar-burning to fat-burning metabolism.
During the fasting period, insulin levels drop, glycogen stores are gradually depleted, and the body begins to mobilize stored fat for energy.
This lowered-insulin environment is where healing begins — allowing cells to regain insulin sensitivity and rest from constant nutrient overload.
B. What Happens Inside During a Fast
Intermittent fasting activates a cascade of cellular and hormonal changes that reverse the very problems sulfonylureas worsen:
- Lower Insulin, Higher Sensitivity
- Fasting allows insulin levels to fall.
- Lower insulin enables fat cells to release stored energy (lipolysis).
- Over time, tissues become more responsive to insulin — meaning the pancreas doesn’t need to work as hard.
- Autophagy and Cellular Renewal
- In the absence of food, cells shift from growth mode to maintenance mode.
- Autophagy — the process of cellular self-cleaning — removes damaged mitochondria and proteins.
- Old and worn-out beta cells undergo apoptosis (programmed death), making way for new, functional insulin-producing cells.
- Reduced Inflammation and Oxidative Stress
- Fasting downregulates inflammatory cytokines like TNF-α and IL-6.
- It improves mitochondrial efficiency, reducing free radicals that damage tissues.
- Improved Lipid Profile and Blood Pressure
- Studies show fasting lowers triglycerides and LDL, raises HDL, and reduces blood pressure.
- These changes collectively lower the risk of cardiovascular events.
C. Protecting the Heart — The Metabolic Advantage
Unlike sulfonylureas, intermittent fasting actually preconditions the heart. When the body becomes metabolically flexible — able to switch between glucose and fat for fuel — heart tissue becomes more resilient to oxygen deprivation.
Animal studies have shown that intermittent fasting reduces infarct size and enhances recovery after ischemic injury. This adaptation mimics the protective process that sulfonylureas block.
In effect, intermittent fasting restores what those drugs remove — the heart’s ability to survive metabolic stress.
D. Clinical and Practical Benefits
Modern research has confirmed what physiology predicts.
A 2019 New England Journal of Medicine review by Mattson et al. summarized the broad benefits of intermittent fasting:
- Improved glucose regulation
- Lower resting insulin and fasting glucose
- Reduced blood pressure and heart rate
- Protection against obesity, fatty liver, and neurodegeneration
- Enhanced cardiac performance and longevity
Patients who incorporate fasting under supervision often see reductions in fasting insulin, triglycerides, and blood pressure within weeks — benefits achieved without adding medications or risking hypoglycemia.
E. Safety Note: Medication Adjustment Is Key
People taking sulfonylureas who wish to try intermittent fasting must do so under medical guidance.
Because fasting naturally lowers blood sugar, continuing the same SU dose could cause dangerously low glucose levels (hypoglycemia).
Physicians may reduce or discontinue these drugs as fasting improves metabolic control — a sign that the body is regaining self-sufficiency.
Intermittent Fasting while on Diabetes Medications
F. The Physiologic Logic
| Parameter | Sulfonylureas | Intermittent Fasting |
|---|---|---|
| Insulin levels | Increased chronically | Decreased, more physiologic |
| Pancreatic effect | Overstimulates beta cells | Allows beta-cell rest and renewal |
| Autophagy | Suppressed | Activated |
| Heart resilience | Impaired (blocks K<sub>ATP</sub>) | Enhanced (mimics preconditioning) |
| Weight | Gain | Loss or normalization |
| Long-term impact | Beta-cell exhaustion | Metabolic rejuvenation |
G. Summary
Intermittent fasting achieves what sulfonylureas cannot — it lowers both glucose and insulin, restores metabolic rhythm, and strengthens the heart.
It treats the cause rather than the symptom, giving the body time to repair itself instead of forcing it to overproduce hormones.
In the next section, we’ll tie these lessons together and show why the real measure of success in diabetes care isn’t a normal glucose number — it’s a metabolically healthy, longer life.
VII. Conclusion: The Healing Power of Rest
Sulfonylureas lower glucose by pushing a tired organ harder, while intermittent fasting heals by letting that organ rest.
The difference mirrors two philosophies of medicine:
- One manipulates numbers;
- The other restores natural rhythms.
Chronic hyperinsulinemia, endothelial dysfunction, and heart disease all stem from the same root—too much energy intake, too often, for too long.
Intermittent fasting corrects that imbalance not by adding another chemical, but by subtracting the excess and allowing recovery.
Modern research and centuries of human experience align: periodic fasting lowers insulin, reduces inflammation, rejuvenates cells, and strengthens the heart.
Meanwhile, sulfonylureas—though affordable and familiar—remain linked with beta-cell exhaustion and higher cardiac mortality.
The path forward is clear. Diabetes care should no longer focus solely on lowering glucose, but on restoring insulin balance, metabolic efficiency, and cardiovascular health.
The ultimate goal is not just to normalize numbers, but to reclaim vitality.
Don’t Get Sick!
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.
Related:
- The Hidden Truth: Diabetes Medications Manage, Not Truly Heal
- How Exercise And Diet Prevent Diabetes Complications Naturally, Powerfully
- Preventing Diabetes Complications Through Sleep, Calmness, and Sobriety
- Natural Supplements Don’t Prevent Diabetes Complications
- Simple Daily Choices That Cut Heart Attack And Stroke Risks
References:
- Roumie, Christianne L., et al. “Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure.” Journal of the American Heart Association, vol. 6, no. 4, 2017, e005379.
https://www.ahajournals.org/doi/10.1161/JAHA.116.005379 - Toombs, Christopher F., Teresa L. Moore, and Ronald J. Shebuski. “Limitation of Infarct Size in the Rabbit by Ischaemic Preconditioning Is Reversible with Glibenclamide.” Cardiovascular Research, vol. 27, no. 4, Apr. 1993, pp. 617–622.
https://doi.org/10.1093/cvr/27.4.617 - Mattson, Mark P., et al. “Effects of Intermittent Fasting on Health, Aging, and Disease.” New England Journal of Medicine, vol. 381, no. 26, Dec. 2019, pp. 2541–2551.
https://www.nejm.org/doi/full/10.1056/NEJMra1905136 - U.S. Food and Drug Administration. “Labeling for Oral Hypoglycemic Drugs of the Sulfonylurea Class.” Code of Federal Regulations, 21 CFR §310.517, Apr. 1, 2019.
n
© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.